Download presentation
Presentation is loading. Please wait.
Published byIsabella O’Brien’ Modified over 9 years ago
1
CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners
2
CARU DeclarationsDeclarations First author – Nigel Beckett – has moved from Imperial College to King’s Health Partners since the NEJM paper was published. As a PROGRESS investigator, Servier have funded speaking at meetings around 2001-3.
4
Blood Pressure & The Very Elderly (aged 80 or more) Population studies suggest better survival with higher levels of blood pressure Worse survival reported in hypertensives with SBP levels below 140 mmHg (Oates et al. 2007) Clinical trials recruited too few. Meta-analysis (n=1670) (Gueyffier et al. 1997) –36% reduction in the risk of stroke (BENEFIT) –14% (p=0.05) increase in total mortality (RISK) Hypertension in the Very Elderly Trial (HYVET) pilot results (n=1273) similar to meta-analysis (Bulpitt et al. 2003)
5
The Trial: International, multi-centre, randomised double-blind placebo controlled Inclusion Criteria: Exclusion Criteria: Aged 80 or more,Standing SBP < 140mmHg Systolic BP; 160 -199mmHg Stroke in last 6 months + diastolic BP; <110 mmHg, Dementia Informed consentNeed daily nursing care Primary Endpoint: All strokes (fatal and non-fatal ) Target blood pressure 150/80 mmHg
6
Statistical Analysis Numbers based on a 35% reduction in all strokes –α= 0.01 ß=0.1 –Stroke event rate of 40/1000 –10,500 years of follow-up required 3 interim analyses planned –Stopped at 2 nd as decrease in stroke and all-cause mortality ITT and PP analyses Other main trial endpoints: total mortality, cardiovascular mortality, cardiac mortality, stroke mortality, heart failure
7
4761 Entered into Placebo Run-in Placebo 1912 Active 1933 916 not randomised 3845 randomised; Western Europe (86) Eastern Europe (2144), China (1526), Australasia (19), Tunisia (70) At end of trial; 1882 still in double blind, 17 vital status not known, 220 in open follow-up
8
Placebo (n= 1912) Active (n= 1933) Age (years)83.583.6 Female60.3%60.7% Blood Pressure: Sitting SBP (mmHg)173.0 Sitting DBP (mmHg)90.8 Orthostatic Hypotension ‡ 8.8%7.9% Isolated Systolic Hypertension32.6%32.3% Baseline data ‡ Fall in SBP ≥ 20mmHg and/or fall in DBP ≥ 10mmHg
9
Baseline Data ( Previous Cardiovascular History ) Placebo (%) Active (%) Cardiovascular disease12.011.5 Known Hypertension89.9 Anti-hypertensive treatment65.164.2 Stroke6.96.7 Myocardial Infarction3.23.1 Heart Failure2.9
10
PlaceboActive Current smoker6.6%6.4% Diabetes (Known DM/ DM treatment/glucose>11.1mmo/l) 6.9%6.8% Total cholesterol (mmol/l)5.3 HDL Cholesterol (mmol/l)1.35 Serum Creatinine (μmol/l)89.288.6 Uric acid (µmol/l)279280 Body Mass Index (kg/m 2 )24.7 Baseline data ( Cardiovascular Risk factors )
11
Blood pressure separation Median follow-up 1.8 years 15 mmHg 6 mmHg
12
All stroke (30% reduction) Placebo IndapamideSR ±perindopril Indapamide SR ±perindopril Placebo P=0.055
13
Total Mortality (21% reduction) Placebo Indapamide SR ±perindopril P=0.019 Placebo IndapamideSR ±perindopril
14
Fatal Stroke (39% reduction) Indapamide SR ±perindopril Placebo P=0.046 Placebo IndapamideSR ±perindopril
15
Heart Failure (64% reduction) P<0.0001 Placebo IndapamideSR ±perindopril Placebo IndapamideSR ±perindopril
16
020.50.20.1 HR95% CI 0.70(0.49, 1.01) 0.61(0.38, 0.99) 0.79(0.65, 0.95) 0.81(0.62, 1.06) 0.77(0.60, 1.01) 0.71(0.42, 1.19) 0.36(0.22, 0.58) 0.66(0.53, 0.82) All Stroke Stroke Death All cause mortality NCV/Unknown death CV Death Cardiac Death Heart Failure CV events ITT – Summary
17
Biochemical Changes from Baseline (2 year cohort) In 2 year cohort there were no significant differences between the groups with regard to change in serum…. Potassium Uric acid Glucose Creatinine At 2 years 73.4% on combination treatment in active group (85.2% placebo)
18
Safety Reported serious adverse events (after randomisation) –448 in the placebo group vs 358 in active (p=0.001) –Only 5 categorised by the local investigator possible SADRs (3 in placebo group, 2 being in active)
19
CARU 4 centres closed in first year due to data quality uncertainties Large large number of patients from Eastern Europe and China Change in shygs (Hg to semiautomatic) Protocol change from DBP 90-109 extended to DBP<110 after 2 years Trial stopped early due to mortality benefit in active treatment group. Last visit 8 months later. 2 nd interim analysis after 6 years of recruitment RR stroke 0.59 (0.4-0.88) p=0.0009 RR all cause mortality 0.76 (0.62-0.93) p=0.007 Final dataset failed to show primary outcome benefit (all stroke) Points worthy of comment
20
CARU ApplicabilityApplicability
21
CARU 2008 Trial of the Year awarded by ImpACT (Important Achievements of Clinical Trials) American Heart Association top ten list for major advances in heart disease and stroke research in 2008 test Achievements of HYVET
22
CARU 102 reported fractures in 3,845 participants, 90 validated (majority femur) 38 active 52 placebo Cox proportional hazard regression adjusted for baseline risk factors Point estimate 0.58 (0.33-1.00) p=0.0498 Other findings from HYVET (1) The effect of treatment based on a diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the HYVET. Peters et al Age Ageing 2010 39: 609-616
23
CARU 3336 pts mean follow up 2.2 years Baseline and annual MMSE Diagnosis of dementia using standard criteria MMSE -1.1 placebo +0.7 active Dementia Placebo 38 cases/1000 pt years Active 33 cases/1000 pt years HYVET-COG Other findings from HYVET (2) Peters et al 2008 Lancet Neurology 7: 683-689.
24
CARU 2656 pts completed a GDS-15 GDS ≥ 6 associated with risk of all cause mortality HR 1.8 (1.4 – 2.3) CV mortality HR 2.1 (1.5 – 3.0) All stroke HR 1.8 (1.2 – 2.8) CV events HR 1.6 (1.2 – 2.1) Each point on GDS at baseline associated with significantly increased risk of fatal and non fatal CV events, all cause mortality and dementia. Depression: Other findings from HYVET (3) Peters et al 2010 Age Ageing 39: 439-445
25
CARU Antihypertensive treatment based on indapamide (SR) 1.5mg (± perindopril) reduced stroke mortality and total mortality in a very elderly cohort. NNT (2 years) = 94 for stroke and 40 for mortality Large and significant benefit in reduction of heart failure events and for combined endpoint of cardiovascular events Benefits seen early Treatment regimen was safe Protocol target of <150/80 mmHg reached in 20% on placebo; 48% on active treatment ISH target reached in 71% (J Hum Hypertens 2011) ConclusionsConclusions
26
CARU
28
Per-Protocol HR95% CIP All stroke- 34%0.46 - 0.950.025 Total mortality- 28%0.59 - 0.880.001 Fatal stroke- 45%0.33 - 0.930.021 Cardiovascular mortality-27%0.55-0.970.029 Heart failure-72%0.17-0.48<0.001 Cardiovascular events- 37%0.51-0.71<0.001
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.